Getinge Reports Strong Q2 2026 Growth Driven by Profitability Gains

CEO Mattias Perjos credited the company's performance to successful product launches and operational efficiency. Acute Care Therapies saw broad gains, while the Sterile Transfer category achieved double-digit growth. Excluding the impact of the tariff refund and currency fluctuations, the adjusted EBITA margin stood at 15.2%, reflecting steady productivity improvements and favorable product mix.

Innovation remains a cornerstone of the company’s strategy, evidenced by the release of new endoscopic vessel harvesting technology and automated endoscope reprocessing systems. In June, the company reached a regulatory milestone by submitting a 510(k) application for its Cardiosave intra-aortic balloon pump to the FDA. To bolster its market position, Getinge also acquired the UK-based distributor Pennamed and opened a new digital perioperative innovation center in Hamburg. Given current customer demand, leadership maintains its forecast for 3–5% organic sales growth for the full year.